Gufic BioSciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Gufic BioSciences is navigating a complex landscape characterized by moderating revenue growth and improving margins. Management's focus on expanding its portfolio of biosimilars and innovative products aligns with the broader industry trend towards higher-margin offerings, which is crucial for enhancing profitability. Despite a stable market share and a fragmented competitive position, the company's strategic initiatives in contract manufacturing and exports are expected to bolster its revenue streams. Vista's financial outlook reflects a cautious optimism, projecting a slight improvement in margins as the company capitalizes on favorable currency dynamics and increasing pricing power within the Indian pharmaceutical sector. The current valuation is deemed fair, suggesting that the stock is trading in line with its intrinsic value, with a modest expected upside. Macro conditions, including stable inflation and favorable liquidity, further support Gufic's growth potential. However, the company must remain vigilant regarding input cost pressures and competitive dynamics. Over the next 12-24 months, key opportunities lie in leveraging its innovative product pipeline and expanding export capabilities, while watchpoints include potential margin pressures and the evolving regulatory landscape
Why We Like This Stock
Things To Watch Out For
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 807 | 820 | 940 | 991 | 1,002 |
| Profit Before Tax (Cr.) | 118 | 94 | 85 | 98 | 97 |
| PBT Margin | 14.7% | 11.4% | 904.3% | 9.9% | 9.7% |
| Net Profit (Cr.) | 89 | 76 | 63 | 72 | 72 |
| Earnings Per Share | 8.9 | 7.6 | 6.3 | 7.2 | 7.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.